亚洲免费av电影一区二区三区,日韩爱爱视频,51精品视频一区二区三区,91视频爱爱,日韩欧美在线播放视频,中文字幕少妇AV,亚洲电影中文字幕,久久久久亚洲av成人网址,久久综合视频网站,国产在线不卡免费播放

        ?

        依普利酮治療原發(fā)性高血壓療效和安全性的系統(tǒng)評價/Meta分析再評價

        2021-10-29 17:55:10張平高存州鄒婧吳愛萍
        中國藥房 2021年20期
        關鍵詞:系統(tǒng)評價原發(fā)性高血壓Meta分析

        張平 高存州 鄒婧 吳愛萍

        中圖分類號 R543;R972 文獻標志碼 A 文章編號 1001-0408(2021)20-2530-08

        DOI 10.6039/j.issn.1001-0408.2021.20.16

        摘 要 目的:對依普利酮治療原發(fā)性高血壓療效和安全性的系統(tǒng)評價/Meta分析進行再評價。方法:計算機檢索PubMed、Embase、Cochrane圖書館、Web of Science、萬方數(shù)據(jù)、中國知網(wǎng)、維普網(wǎng)等,收集依普利酮治療原發(fā)性高血壓的系統(tǒng)評價/Meta分析,檢索時限均為建庫起至2021年6月24日。篩選文獻并進行資料提取后,采用PRISMA聲明評價納入文獻的報告質(zhì)量,采用AMSTAR 2量表評價納入文獻的方法學質(zhì)量,采用GRADE方法評價納入文獻結局指標的證據(jù)質(zhì)量,并對納入文獻的療效和安全性指標評價進行匯總。結果:共納入8篇系統(tǒng)評價/Meta分析,其中5篇為系統(tǒng)評價、3篇為Meta分析,共包含73個結局指標。PRISMA評分為7.5~23.5分,其中≤15分的有6篇(75.0%),>15~<21分的有1篇(12.5%),≥21分的有1篇(12.5%)。AMSTAR 2評價結果顯示,2項研究的方法學質(zhì)量等級為低級,6項研究為極低級。GRADE證據(jù)質(zhì)量評價結果顯示,高質(zhì)量指標有3個,中質(zhì)量指標有24個,低或極低質(zhì)量指標有46個;導致降級的因素主要為局限性、不一致性、不精確性及發(fā)表偏倚。在治療有效性方面,與安慰劑比較,依普利酮可顯著降低患者的診室血壓和24 h動態(tài)血壓;其在降低診室血壓方面的效果顯著優(yōu)于其他降壓藥物或與其他降壓藥物相當。依普利酮降低診室收縮壓的效果不及螺內(nèi)酯和依那普利,或優(yōu)于鈣通道阻滯劑、依那普利和血管緊張素受體拮抗劑,或與鈣通道阻滯劑和依那普利相當;依普利酮降低診室舒張壓的效果不及螺內(nèi)酯、鈣通道阻滯劑和依那普利,或與依那普利相當,而優(yōu)于血管緊張素受體拮抗劑。在安全性方面,依普利酮的不良反應、嚴重不良反應和高鉀血癥發(fā)生率與安慰劑比較差異均無統(tǒng)計學意義,或其不良反應發(fā)生率顯著高于安慰劑;該藥的不良反應、嚴重不良反應發(fā)生率與其他降壓藥物比較差異均無統(tǒng)計學意義。結論:依普利酮治療原發(fā)性高血壓的療效和安全性均較好,但目前相關系統(tǒng)評價/Meta分析的方法學質(zhì)量整體較低,且證據(jù)水平普遍為中、低或極低,可能會降低該結論的真實性與有效性,應謹慎解讀。

        關鍵詞 依普利酮;原發(fā)性高血壓;療效;安全性;系統(tǒng)評價;Meta分析;再評價

        Efficacy and Safety of Eplerenone in the Treatment of Essential Hypertension: Reevaluation of Systematic Review/Meta-analysis

        ZHANG Ping,GAO Cunzhou,ZOU Jing,WU Aiping(Dept. of Basic Medicine, Guizhou College of Health Professions, Guizhou Tongren 554300, China)

        ABSTRACT? ?OBJECTIVE: To reevaluate the systematic review/Meta-analysis of efficacy and safety of eplerenone in the treatment of essential hypertension. METHODS: Retrieved from PubMed, Embase, Cochrane Library, Web of Science, Wanfang database, CNKI, VIP, systematic review/Meta-analysis about eplerenone in the treatment of essential hypertension were collected from the inception to June 24th,2021. After literature screening and data extraction, the quality of included literatures were evaluated with PRISMA statement; methodology quality of included literatures were evaluated with AMSTAR 2 scale; GRADE method was adopted to evaluate the evidence quality of outcome measures. Efficacy and safety index evaluation of included literatures were summeried. RESULTS: A total of 8 systematic reviews/Meta-analyses were included, involving 5 systematic reviews and 3 Meta-analysis, including 73 outcome indicators. PRISMA scores ranged from 7.5 to 23.5, including 6 literatures (75.0%) with≤15 points, 1 (12.5%) with >15-<21 points and 1 (12.5%) with ≥21 points. The results of AMSTAR 2 evaluation indicated that the methodological quality of 2 studies was low, and that of 6 studies was very low. GRADE quality evaluation results showed that there were 3 high quality indicators, 24 medium quality indicators and 46 low or very low quality indicators; the factors contributed to downgrading evidence quality were limitation, inconsistency, imprecision and publication bias. In terms of efficacy, compared with placebo, eplerenone could significantly reduce clinical blood pressure (CBP) and 24-hour ambulatory blood pressure (ABP). Its effect in reducing CBP was significantly better than other antihypertensive drugs or equivalent to other antihypertensive drugs. The effects of eplerenone on reducing clinical systolic blood pressure was not as good as spironolactone and enalapril, or better than calcium channel blocker, enalapril and angiotensin receptor antagonist, or equivalent to calcium channel blocker and enalapril; the effect of eplerenone on reducing clinical diastolic blood pressure was not as good as spironolactone, calcium channel blocker and enalapril, or as good as enalapril, but better than angiotensin receptor antagonist. In terms of safety, there was no significant difference in the incidence of ADR, serious ADR or hyperkalemia caused by eplerenone, compared with placebo, or the incidence of ADR was higher than that of placebo. There was no statistical significance in the incidence of ADR or serious ADR, compared with other antihypertensive drugs. CONCLUSIONS: Efficacy and safety of eplerenone in the treatment of essential hypertension was good,but in view of the poor methodological quality of systematic reviews or Meta-analysis and the low or very low level of outcome indicator evidence, the authenticity and effectiveness of the conclusion will be reduced, so that those indcaters should be interpreted carefully.

        猜你喜歡
        系統(tǒng)評價原發(fā)性高血壓Meta分析
        高壓氧治療血管性癡呆隨機對照試驗的Meta分析
        原發(fā)性高血壓患者血清同型半胱氨酸水平與靶器官損害的關系
        依托團隊服務的社區(qū)原發(fā)性高血壓患者家庭血壓自我檢測模式的效果評價
        纈沙坦聯(lián)合氨氯地平在社區(qū)原發(fā)性高血壓合并糖尿病老年患者的治療效果
        利卡汀聯(lián)合肝動脈栓塞化療治療中晚期肝癌的效果及安全性的系統(tǒng)評價
        血小板與冷沉淀聯(lián)合輸注在大出血臨床治療中應用的Meta分析
        細辛腦注射液治療慢性阻塞性肺疾病急性加重期療效的Meta分析
        中藥熏洗治療類風濕關節(jié)炎療效的Meta分析
        丹紅注射液治療特發(fā)性肺纖維化臨床療效及安全性的Meta分析
        厄貝沙坦氫氯噻嗪治療原發(fā)性高血壓1~2級患者療效分析
        今日健康(2016年12期)2016-11-17 19:43:16
        一区二区三区国产免费视频| 一区二区三区在线视频爽| 国产免费破外女真实出血视频| 欧美另类视频在线| 一本大道久久东京热无码av| 欧美日韩国产在线人成dvd| 国产丝袜在线福利观看| 最近更新中文字幕一区二区| 日韩av无码社区一区二区三区| av永久天堂一区二区三区| 亚洲精品乱码久久久久久蜜桃图片| 精品人体无码一区二区三区 | 亚洲日本人妻少妇中文字幕| 亚洲国产精品久久精品 | 免费av片在线观看网站| 中文字幕亚洲综合久久| 熟女免费视频一区二区| 曰韩少妇内射免费播放| 成年站免费网站看v片在线| ā片在线观看免费观看 | 国产av午夜精品一区二区入口| 国产亚洲午夜精品久久久| 99久久精品无码一区二区毛片| 美女高潮无遮挡免费视频| 国产精品1区2区| 青青青伊人色综合久久| 狼狼色丁香久久女婷婷综合| 制服丝袜一区二区三区| 国产成年无码v片在线| 97欧美在线| 精品久久免费一区二区三区四区| 成人影院视频在线播放| 中文字日产幕码三区的做法大全 | 91久久国产自产拍夜夜嗨| 日韩av中文字幕亚洲天| 色佬精品免费在线视频| 中文字幕久久熟女蜜桃| 精品国产制服丝袜高跟| 国产高清黄色在线观看91| 日本一区二区三区丰满熟女 | 麻豆成人在线视频|